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ABSTRACT 
Abnormal blood vessel proliferation in the retina is the physical manifestation 
promoting blindness in neovascular retinopathies. Neovascular retinopathies include 
diabetic retinopathy, retinopathy of prematurity, and the 'wet form' of macular 
degeneration, and constitute the foremost cause of vision loss in developed nations. 
Uncontrolled angiogenesis is responsible for the aberrant neovascular phenotype. 
Vascular beds become chaotic and extend to form pre-retinal membranes covering the 
retinal tissue, and consequently structurally and functionally hinder vision. Elucidating 
the molecular biological events leading to the unregulated angiogenic surge will help in 
developing molecular treatments targeting the neovascular phenotype. 
Tubedown-1 (Thdn-1) is a novel protein expressed highly in adult ocular blood vessels. 
Tbdn-1 is homologous to theN-terminus ofyeast Natl and co-purifies with an 
acetyltransferase activity. Previous data implicates Tbdn-1 as a negative regulatory 
modulator of capillary formation in adults. Furthermore, Thdn-1 protein expression is 
down-regulated in retinal blood vessels of patients with proliferative diabetic retinopathy 
compared to its high expression in normal retinal blood vessels. The objective of this 
thesis was to further investigate the role of Tbdn-1 in retinal vasculature by studying a 
mouse model enabling conditional knockdown of Tbdn-1 specifically in endothelial cells. 
Based on previous results, the hypothesis was suppression of Tbdn-1 in endothelium 
would result in an increase retinal angiogenesis. Histological analysis of retinas from 
mice demonstrating suppression of the Tbdn-1 protein revealed the presence of pre-
retinal membranes coinciding with increased retinal neovascularization. The pre-retinal 
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membranes also displayed the proliferation of glial cells and myofibrobasts, a 
decreased expression of basement membrane constituent heparan sulfate proteoglycan. 
Retinas exhibiting a prolonged down-regulation of Tbdn-1 showed an increase the size 
of pre-retinal membranes. Furthermore, the neovascular phenotype resulting from Tbdn-
1 down-regulation appeared to be specific to the delicate retinal tissue, as it was not 
observed in other tissues. These results reinforce the hypothesis that Thdn-1 functions to 
dampen capillary formation in vivo. Loss ofTbdn-1 expression in the retina may alleviate 
a constraining force on endothelial cell remodeling allowing the outgrowth of endothelial 
cells to form neovascular networks. 
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1 INTRODUCTION 
1.1 The Retina 
The retina is the principal ocular tissue responsible for visual perception. Retinal 
tissue lines the back two-thirds of the eyeball and is structurally divided into seven 
distinct layers responsible for the initial construction of an image (see Fig. 1-1 ). These 
layers are distinguished by the presence of neuronal cell bodies or bundles of synaptic 
connections establishing intraretinal communication. Light enters the eye through the 
anterior eye segment and is focused upon the retina via the cornea (the transparent 
membrane covering the anterior eye) and the lens. Light stimuli must transverse the entire 
layered retinal tissue before the photons are detected and converted into electrical 
impulses at the sensory photoreceptor cells located at the farthest outer retinal layer. 
Intricate neural circuits spanning the retinal tissue allow the vertical propagation of 
electrical and chemical messages from the photoreceptor cells to the inner nuclear and 
ganglion cell layers. The signal is then propagated laterally until reaching the optic nerve, 
the point at which the signal leaves the eye and travels to the brain for further visual 
process mg. 
The retina may be divided into the vascular retinal fraction and the avascular 
retinal fraction. The innermost layers of the retina (the retinal fraction directly adjacent to 
the gel-like vitreous) comprise small retinal blood vessels that receive its blood supply 
from the central retinal artery. Adjacent endothelial cells lining these blood vessels 
adjoin to form seals or tight junctions, the first component constituting blood-retinal 
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batTier. To ensure sharp visual acuity the outer photoreceptor fraction is completely 
avascular and acquires its metabolic needs &om the underlying tissue, the highly vascular 
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Ia: A H&E s1ained sagittal section through a mouse eye illuscrates the major anatomjcal parts of the eye. 
The anterioc' eye segment consists of the cornea (the transparent membrane co .. ·ering the eye .,.,fticb focuses 
light onto the recina) and the iris (which corurots the amount of light entering the eye). ln mice. the lens 
occupies most of the vitreous chamber whik in humans the lens is smaller leaving most oflhe vilttOuS 
space unoe<:upied. The vitreous is an acell~•lar, relrujvely inert, viscous gel·likc material located directly 
adjacent to the retina. Although lhe vitreous chamber appears \'atanl. it oonsisb of hyaluronic acid and 
highly dispersed collagen. The retina lines the back (posterior segment) of the eyeball and functions as a 
peripheral sense organ. It is attached to lhe underlying hig,bly vasc:ular choroid. which serves the metabolic 
demands of tbe outer retina. (The detachment of the retina from the choroid seen in this picture is merely 
an artifact of tissue processing..) 
lb: Figure lb is a ma_gnifted view of the boxed region oflhe retina in tig.ure Ia. The inner limitin& 
membrane {ILM) of the recina fonns a diffusion barrier separating the retina from the vitreOus. The retina 
consists of7 layers: the ganglion cctllaytt (GCL). the inner plexifonn layer (IPL), the inner nuclear layer 
(INL), the outer plexifonn layer (OPL).lhe outer nuclear layer (ONL). the photoreceptor'S (PHR) and the 
retinal pi_gn1ent epithelium (RPE). The IPL and OPL contain cell axons establishing synaptic connections 
while the INLand GCL contain cellular nuclei responsible for propagation and modification of the stimuli. 
The ONL contains the cell bodies of the photoreceptor oells. ibe choriocapillaries nourish the avasc:ular 
regions of the outer retina. 
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choriocapillaries. These capillaries are fenestrated and characteristically leaky to 
facilitate the transport of essential nutrients from the choroidal blood supply to the retinal 
pigment epithelium (RPE). Fluid from the choriocapillaries pools beneath the RPE (a thin 
layer of cubical shaped cells lying directly below the photoreceptors) and is transported 
to the outer retina by specific transport mechanisms designed to remove waste from the 
sensory retinal cells while also providing the cells with essential nutrients. RPE cells also 
adjoin to form tight junctions constituting the second component of the blood retinal 
barrier (Carnpochlaro 2000). 
The vascularity of the normal adult retina is quiescent. Adult retinal endothelial 
cells (the cells that line blood vessels) are among the most stable cells in the body with a 
turnover rate of approximately 25 years (Paques et al. 1997). Maturation of retinal blood 
vessels is marked by the co-localization of the vascular network with supporting cells 
called pericytes. Peric:ytes are a class of smooth muscle cells with contractile properties 
which function to constrain endothelial cell remodeling while promoting endothelial cell 
survival. Pericytes co-localized with endothelial cells secrete the growth factor Vascular 
Endothelial Growth Factor (VEGF), which under a normal physiological concentration 
enhances endothelial cell survival through the inhibition of apoptosis (Wenbiao et al. 
2002). Pericytes in contact with endothelial cells also activate Transforming Growth 
Factor-B (TGF-B), a multifunctional growth factor implicated in the inhibition of 
endothelial cell proliferation (D'Amore 1994). Loss ofthe intimate association of 
pericytes with the vascular bed is thought to render endothelial cells prone to fluctuations 
in the local microenvironment Vision obscuring diseases of the retina are often initially 
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characterized by 'pericyte dropout', rendering 
pathologic disease progression. 
1.2 Neovascular Retinopathies 
endothelial cells susceptible to 
Blinding proliferative retinopathies, such as proliferative diabetic retinopathy 
(PDR), branch vein retinal occlusion, and retinopathy of prematurity (ROP), are leading 
causes of vision loss in the industrialized world and are primarily characterized by 
aberrant retinalneovascularization. Neovascularization occurs by a process called 
angiogenesis, the formation of new blood vessels by recycling differentiated endothelial 
cells (Conway et al. 2001). Angiogenesis is vital to the development ofthe embryonic 
vascular network and remains an active process in the adult, though restricted to highly 
specific conditions and vascular beds such as wound healing and female reproduction. 
Angiogenesis is also the mechanism responsible for nascent blood vessel formation in 
pathological settings such as tumor progression as well as the overgrowth of retinal blood 
vessels (Timar et al. 2001 ). In normal conditions angiogenesis is accomplished through a 
tightly regulated collaborative mechanism involving degradation of the surrounding 
extracellular matrix, activation of the newly exposed endothelial cells, migration and 
proliferation of these cells, followed by their assembly into tubular structures (Conway et 
al. 2001). The quiescence of the retina is derived from a balance between pro-angiogenic 
and anti-angiogenic modulators (Semenza 2003). However, the diseased retina exhibits a 
disruption in the molecular profile controlling the angiogenic process enabling a 
prevalence of pro-angiogenic stimuli. The retina is sensitive to the heightened 
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concentrations of pro-angiogenic factors, which manifests as abnormal retinal 
neovascularization (Speicher et al. 2003). 
Neovascular retinopathies involve an un_yielding transformation retinal 
microvasculature and its associated extracellular matrix. Cellular proliferation at the 
interface of the retina and vitreous tissue results in the formation of preretinal membranes 
or retinal lesions, an occurrence evident in both ROP and PDR (Speicher et al. 2003; 
Smith 2003). Glial cells, myofibroblasts, endothelial cells and extracellular matrix 
proteins are the common residents constituting these fibrovascular membranes 
(Bochaton-Piallat et al. 2000). The contraction or migration of the glial and 
myofibroblast cell types promotes extracellular matrix remodeling, which may result in 
tractional detachment of the retina from the underlying RPE (Bochaton-PiaHat et al. 
2000; Mishima et al. 1989; Lewis et al. 2003). Retinal detachment is a major source of 
vision loss in patients with both ROP and PDR Kohner 1993; Good et al. 2001). The 
nascent blood vessels characteristic of preretinal membranes are often functionally 
impaired and leaky, a consequence of a breakdown of the blood-retinal barrier. Blood 
cells, proteins and plasma pass through or between the diseased vascular walls with the 
potential for ocular edema. The collection or building of fluid in the delicate retina and 
vitreous may manifest as vitreal haemorrhage, also a significant cause of blindness 
associated with proliferative retinopathies (Cai et 2003). 
Although the initial insult which fuels a molecular cascade promoting the 
neovascular phenotype differs between proliferative retinopathies, the indirect stimulus 
driving retinal neovascularization is common among these diseases. Hypoxia is the 
major stimulus responsible for the surge of events leading to a pro-angiogenic state in the 
normally quiescent retinal tissue (Smith 2003; Khan et al. 2003; Semenza 2003; 
Stefansson 1990). Although the stimulatory role of hypoxia is not completely 
understood, hypoxic conditions are detected by an oxygen sensing cytosolic heme protein 
which responds to low oxygen tension by generating free radicals (Campochiaro 2000; 
Cai et al. 2004). The free radicals activate transcription factors, including Hypoxia 
Inducible Factor-1 (HIF-1). The HIF-la subunit exhibits an increased lifespan in 
response to a decreased oxygen concentration and forms a dimmer by binding to the 
constitutively expressed HIF-1 p subunit. Together these subunits function as a 
transcription factor, activating proteins with a hypoxia responsive element (Campochiaro 
2000; Semenza 2003). Hypoxic conditions result in an increased expression of the potent 
endothelial cell mitogen and permeability agent VEGF, an important growth factor 
implicated in the initiation and progression of proliferative retinal diseases (Khan et al. 
2003; Aiello et al. 2000; Witmer et al. 2003; Zachery 2003). Transgenic mice 
demonstrating VEGF overexpression develop severe retinal neovascularization 
resembling proliferative retinopathy, which advances to retinal detachment (Ohno-Matsui 
et al. 2002; Okamoto et al. 1997). Insulin -Like Growth Factor-1 (IGF -1) is another 
hypoxia responsive cytokine shown to mediate blood vessel formation and exhibits 
increased expression in patients with an overgrowth of retinal blood vessels (Khan et al. 
2003; Cai et al. 2002; Boulton et al. 1997). 
Perturbed expression of basement membrane constituents are also documented in 
neovascular retinopathy patients (Ljubimov et 1996). Vascular basement membrane 
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proteins include laminin, collagen I, III and IV, heparan sulfate proteoglycans 
(HSPG), and fibronectin. These proteins form a structural scaffold to support blood 
vessel integrity while also providing regulatory molecular signals for endothelial cells. 
Altered expression of such constituents renders endothelial cells exposed and thus 
vulnerable to the pro-angiogenic microenvironment. Also, mitogen-promoting growth 
factors, such as basic Fibroblast Growth Factor (bFGF), are sequestered in extracellular 
matrices (ECM) with matrix degradation releasing the growth factors thereby potentiating 
neoangiogenic activity (Rusnati 1996). Deviations in the expression of many other 
growth factors (such as PDGF, HGF, Ang-1, Ang-2) integrins (the receptors through 
which ECM proteins signal), and matrix metalloproteinases (proteins which regulate 
ECM degradation) are also implicated in the pathogenesis of neovascular retinopathies 
(Khan et al. 2003; Takagi 2003; Ljubimov et al. 1996; Friedlander et al. 1996; Au et al. 
2002). 
1.3 Treatment for Neovascular Retinopathies 
Pan-retinal or scatter laser photocoagulation is the first-line therapeutic option for 
patients with proliferative retinopathies. A patient receiving laser treatment is subjected 
to hundreds or even thousands of bums throughout the peripheral retina while preserving 
the centrally located macula, the area of the retina accounting for 80% of vision in 
humans. Laser-mediated destruction of the photoreceptors, the highest oxygen consumers 
in the retina, results in their replacement with glial cell scar tissue. Ultimately, the 
destruction of the photoreceptors facilitates the diffusion of oxygen from the choroid to 
the ischemic regions of the retina (\Vilson et al. 2003). Thus, the therapeutic effect of 
laser treatment arises from relieving retinal hypoxia and consequently destroying the 
source of the chaotic angiogenic growth factor expression. 
Laser treatment contains a window of opportunity for a beneficial outcome with 
disease progression negatively correlating with a favorable response (Speicher et al. 
2003). If administered early in disease progression, laser therapy can prevent severe 
vision loss by 50 to 60% (ETDRS 1985). Unfortunately, timely treatment is often 
difficult due to the late presentation of symptoms. Also, laser surgery cannot rescue 
visual impairment previously incurred by neovascular retinopathy (Speicher et al. 2003). 
This treatment is ablative and mechanistically involves the destruction of retinal tissue 
with treatment itself responsible for some degree of permanent vision loss. Sight-
threatening side effects such as loss of peripheral vision, reduced night vision, and 
decreased visual acuity are also inherent in the destruction of the peripheral retina (Aiello 
1997). 
Recent research has focused on designing therapies to target the molecules 
involved in both the onset and progression of retinal disease, in hope of complimenting or 
replacing laser surgery. VEGF is an appealing target for molecular therapy due to its 
major proliferative action on endothelial cells and increased expression early in disease 
development Models countering VEGF expression in animal models of proliferative 
retinopathy include targeting its expression through the use of small interfering RNA 
(Reich et al. 2003), gene transfer of soluble VEGF receptors (Bainbridge et al. 2002), 
anti-sense oligonucleotides targeting VEGFR2 (the receptor which relays the mitogenic 
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properties of VEGF), and VEGF specific monoclonal antibodies (Mechoulru:n et al. 
2003). These models have been successful in preventing retinal neovascularization. 
However, they do not completely or consistently rescue pre-existing pathology. 
Currently, there are only two molecular-based drugs in clinical trails to combat diabetic 
proliferative retinopathy. The first is a selective inhibitor ofPKC j3ll, a protein involved 
in intracellular signaling in response to both VEGF and IGF-1. The second drug, 
octreotide acetate, combats IGF-1 mediated signaling. Octreotide acetate is a 
somatostatin analogue which inhibits the phosphorylation of the IGF-1 receptor tyrosine 
kinase, therefore inhibiting signaling through this pathway. Both of these drugs are 
designed for the prevention and/or treatment of very early stage proliferative diabetic 
retinopathy (Speicher et al. 2003). Identification of novel proteins, interactions and 
pathways involved in the pathogenesis of retinal disease will undoubtedly facilitate the 
breakthrough of molecular based treatments to both prevent and cure neovascular 
retinopathy. 
1.4 Tubedown-1 
Tubedown-1 (Tbdn-1) is a recently identified protein isolated from an embryonic 
endothelial cell line (IEM) (Gendron et al. 2000). IEM cells are an attractive model for 
studying molecular characteristics of endothelial cells because of their ability to form 
capillary-like structures in vitro and emulate normal blood vessel formation in embryo 
chimeras in vivo (Gendron et al. 1996). Tbdn-1 is highly expressed in quiescent IEM cell 
cultures. Upon stimulation with endothelial cell stimulants bFGF and Leukemia 
Inhibitory Factor (LIF), the IEM cells remodel to form capillary-like structures 
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coinciding with a decreased protein expression ofThdn-1 (Gendron et al. 2000). The 
Tbdn-1 protein is also down-regulated during the out-growth ofrheus RF/6A retinal-
choroidal endothelial cells to form tubular structures compared to their quiescent state 
(Gendron et al. 2001). Furthermore, targeted suppression ofThdn-llevels in RF/6A 
cells using an antisense eDNA construct specific for Tbdn-1 (ASTBDN-1) results in a 
significant increase in capillary number compared to control cells expressing normal 
levels ofThdn-1 (Paradis et al. 2002). Together, this data suggests that Tbdn-1 may 
function to dampen capillary formation in vitro. 
Tbdn-1 is expressed highly in developing vasculature during embryogenesis; 
however, Tbdn-1 expression in the adult is restricted to ocular endothelium, 
endocardium, bone marrow capillaries, and blood vessels of regressing ovarian follicles 
(Gendron et al. 2000). In vivo, Tbdn-1 expression is specifically suppressed in retinal 
blood vessels of human patients with PDR compared to its high expression in normal 
retinal blood vessels (Gendron et al. 2001). During embryogenesis, the developing 
posterior ocular tissue is nourished by the transient hyaloid vascular network. The 
hyaloid artery and branches (vasa hyaloidea propria) nourish the developing posterior eye 
while the anterior and posterior tunica vasculosa lentis nourish the developing lens (Ito 
1999). The hyaloid vascular network regresses late in embryonic life and in mice the 
involution of hyaloid vascular endothelial cells is complete by post-natal day 30 (Smith 
2002). In humans, failure of the hyaloid vascular network to regress results in persistent 
fetal vasculature (PFV), a potentially blinding disease. TGF-{32 null embryos exhibit a 
persistent hyaloid mass within the vitreal chamber resembling PFV in humans. This 
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pathological hyaloid mass also shows suppression of the Tbdn-1 protein. 
Immunohistochemical analysis has shown that Tbdn-1 is expressed the hyaloid vessels 
and tunica vasculosa lentis layer of blood vessels nourishing the lens of a fetus) of a 
human eye at 14 weeks of gestation (Paradis et al. 2002), prior to the remodeling events 
leading to the regression ofthis vascular bed. Together, this implicates Thdn-1 as a 
necessary caveat in vitreal blood vessel regression during development (Paradis et al. 
2002). Collectively, these results suggest that Tbdn-1 fi.mctions in dampening capillary 
formation in vivo. 
Although the mechanistic action of Thdn-1 remains largely unknown, its activity 
may be regulated through acetylation. Tbdn-1 is homologous to theN-terminus 
acetyltransferase subunit of yeast NAT1 (Gendron et al. 2000). Immunopredpitates 
prepared using an anti-Tbdn-1 specific antibody demonstrate an acetyltransferase 
activity, which may represent an autoacetylation reaction ofTbdn-1 (Gendron et al. 
2000). The autoacetylation of Thdn-1 may likely regulate its activity by potentially 
modifying DNA binding and/or its interaction with other proteins. Tbdn-1 also contains a 
sequence motif homologous to the tetracotripeptide repeat, a motif known to mediate 
protein-protein interactions (Gendron et al. 2000). Tbdn-1 may fi.mction to restrain 
endothelial cell remodeling through these mechanisms. 
1.5 Rationale for Current Study 
Angiogenesis is a multi-factorial process. Its proper execution is accomplished by 
the tight regulation of a host of factors including growth factors, receptors, integrins, and 
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extracellular matrix elements. Unregulated and unrelenting angiogenesis is witnessed in 
several disease processes including abnormal retinal neovascularization, where blood 
vessel proliferation compromises vision. Treatments targeted at defusing angiogenesis 
may alleviate blindness diseases caused by an uncontrolled grovvth of retinal blood 
vessels, such as in PDR, ROP and the 'wet form' of macular degeneration. Because 
angiogenesis is regulated by such a wide host of factors, it seems logical that an effective 
treatment will target more than one facet of the angiogenic process. A thorough 
understanding of the molecules and molecular cascades characteristic of normal and 
diseased retinal biology will facilitate the development of anti-angiogenic treatments. 
Thdn-1 was isolated from retinal endothelial cells in an attempt to identify and 
characterize novel regulatory molecules involved in capillary formation (Gendron et al. 
2000). Preliminary data suggests that Thdn-1 is a necessary contributor to the 
maintenance of normal vascular homeostasis (Gendron et al. 2000; Gendron et al. 2001; 
Paradis et al. 2002). The objective of this study was to further characterize the regulatory 
function of Thdn-1 in retinal capillaries to further uncover of molecular mechanisms in 
vascular retinal biology. 
1.6 Overview of1.Vethodology for Current Study 
Characterization of the role of Tbdn-1 in capillary formation is analyzed in this study 
using a bitransgenic mouse model enabling conditional knockdown of endothelial-
derived Tbdn-1 (see Fig 1-2). The mouse system utilizes two separate gene constructs 
driven by two distinct promoters: tie-2 promoter and the tetracycline response 
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clement (pI Rf.) (for,.., •e" sec Zhu el ul. 2002). Tie-2 is an endothelial cell <peeific 
promol•"f and controls the expression of the I"C\cnt lei trans,.:tivator protein (nTA). The 
pl Rl\ dn'c.. the expression of a specific ASTBD~·I eDNA. The introduction of an 
CXOSCROU.\ 8SCnl, dOX)C)Ciine (Dox). 10 lbe buwy S)Sicm turns the sy<lem ·on' and 
instisotcs a dccreiLo;e in Tbdn-1 protein expresl>ion. Spccificully. Dox ,.,;n bind to the 
n JA protein resulting in a conformational change. lhe nc\\<ly conlbrmed rtTA can then 
bind to its specific binding site within the TRE promoter nllo\\<ingthe expression of an 
ASTBDN·l eDNA. decreasing endogenous lbdn-1 protem cxprc.sion. In the absence of 
Dox. the nrA "ill not bind to theTRE promoter and c.>n«:qucnd) there "ill 001 be a 
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2.2 ABSTRACT 
Purpose. Identification of novel proteins involved in retinal neovascularization may 
facilitate new and more effective molecular based treatments for proliferative 
retinopathy. Tubedown-1 (Tbdn-1) is a novel protein which shows homology to the yeast 
acetyltransferase subunit NATl and co-purifies with an acetyltransferase activity. Tbdn-1 
is expressed in normal retinal endothelium but is specifically suppressed in retinal 
endothelial cells :from patients with proliferative diabetic retinopathy. The purpose of this 
study was to investigate the importance of Tbdn-1 expression in retinal blood vessels in 
vivo. 
Methods. A bitransgenic mouse model enabling conditional knockdown of Tbdn-1 
specifically in endothelial cells was produced and studied using histological and 
immunohistochemical techniques. 
Results. Tbdn-1 suppressed mice developed retinalneovascularization with intra and 
preretinal fibrovascular lesions similar to human proliferative retinopathies. Retinal 
lesions observed in Tbdn-1 suppressed mice increased in severity with prolonged 
suppression of Tbdn-1. In comparison to normal retina, the retinal lesions displayed 
alterations the basement membrane of blood vessels and in the distribution of glial and 
myofibroblastic cells. Moreover, the pathological consequences of Tbdn-1 knockdown in 
endothelium were restricted to the retina. 
Condusim1s. These results indicate that the maintenance of Tbdn-1 expression is 
important for retinal blood vessel homeostasis and for controlling retinal 
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neovascularization adults. Restoration of Tbdn-1 protein expression and/or activity 
may provide a novel approach for treating proliferative retinopathies. 
1.3 
In blinding ocular diseases such as proliferative diabetic retinopathy (PDR) and 
retinopathy of prematurity (ROP), retinal ischemia progresses to a proliferative stage 
involving both neovascularization and fibrosis of the retina resulting in the formation of 
preretinal membranes (1- 8). Membranous traction may result in retinal detachment, a 
significant cause ofblindness associated with both PDR and ROP (1-8). Laser 
photocoagulation administered to peripheral regions of the retina may reduce blindness in 
patients with neovascular retinopathies (1-8). However, this treatment is ablative and may 
not prevent sight-impairing complications associated with neovascular retinopathies (1-
8). Elucidating the molecular processes of proliferative retinal disease and designing 
therapies to target molecular abnormalities may offer a means to replace laser surgery 
and prevent associated complications. 
The molecular events leading to the angiogenic phenotype in PDR and ROP is 
mediated by increased expression of pro-angiogenic growth factors (vascular endothelial 
growth factor [VEGF], basic fibroblast growth factor [bFGF] and insulin-like growth 
factor [IGF-1]) (5, 9-1 Integrins, extracellular matrix (ECM) components and glial 
cells also contribute to pathologic neovascularization in PDR (5, 1 3). Increased 
production ofVEGF in the retina is likely the determining factor in initiating the 
proliferative phase evident in later stages of diabetic retinopathy (DR [9-1 0, 14-15]). 
Treatments specifically targeting either VEGF and its receptors, or specific integrins have 
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been effective in preventing or reducing retinal neovascularization animal models (9). 
However, these treatments do not completely or consistently rescue pre-existing 
pathology. Since a range of angiogenic factors are present in the microenvironment 
promoting retinal blood vessel proliferation, targeting of one type of factor for anti-
angiogenic therapy may not completely counter the neovascularization evident in 
proliferative retinopathies. The characterization of common regulators acting in diverse 
angiogenic pathways will be key in identifying targets which could have a more global 
effect on controlling retinal neovascularization. 
Tubedown-1 (Tbdn-1) is a mammalian homologue of the yeast 
acetyltransferase subunit NAT1 (16). Tbdn-1 expression is regulated during 
development and becomes restricted to normal ocular endothelial cells, atrial 
endocardium, blood vessels of regressing ovarian follicles and bone marrow capillaries in 
adults (16-17). We have found that Tbdn-1 expression is suppressed in retinal blood 
vessels of neovascular areas in patients with PDR (17). Both in vitro experiments and in 
vivo observations have suggested that Tbdn-1 suppression in retinal endothelial cells 
leads to increased angiogenesis (16-18). Collectively, these data have led us to 
hypothesize that Tbdn-1 the adult functions to suppress retinal neovascularization in 
vivo. In order to directly examine ifTbdn-1 is an important regulator of retinal 
neovascularization vivo, we have generated a binary antisense TBDN-1 (ASTBDN-1) 
transgenic mouse model driven by the TIE2 pan-endothelial promoter to enable 
conditional knockdown ofTbdn-1 expression endothelial cells. Here we present vivo 
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evidence for the requirement of Tbdn-1 expression for the maintenance of normal adult 
retinal vascular homeostasis. 
2.4 1YETHODS 
Endothelial specific conditional knockdown of Tbdn-1 in a bitransgenic mouse model 
To facilitate conditional knockdown ofTbdn-1 in endothelial cells in mice, two 
different lines of transgenic mice were derived. For the construction of the first line, the 
BamHIIPvuii fragment from pcDNA3.1/Zeo-ASTBDN-1 8) containing the antisense 
eDNA fragment sequence 1-1413 of TBDN-1 was inserted into the pTRE vector 
(Clontech, Palo Alto California) at the BamHI and Pvuii sites. This antisense TBDN-1 
fragment 1413-1 does not produce aberrant proteins that could confer toxic and non-
specific effects. The resulting construct pTRE/ASTBDN-1 was digested with AatH and 
Pvull. The fragment containing the TRE promoter followed by ASTBDN-1 
(TRE/ASTBDN-1) was used to create FVB transgenic mouse lines (Transgenic Core 
Facility at Children's Hospital Research Foundation [Cincinnati, Ohio]). 
Construction of the second line of transgenic mice was as follows: A DNA 
fragment encompassing coding sequences for rtTA followed by the SV 40 poly A site 
were amplified by PCR from the pTet-On vector (Clontech, Palo Alto California) using 
following primers: 5' -CGGCCCCGAA TT AA TATGGCTAGATTA-3' 5'-
TCCATTTTAGCGGCCGCAGCTCCTGAA-3'. The purified amplicon was digested 
with Hindiii and Noti, and inserted into the pHHSDKXK construct (19) previously 
digested with HindiH and removing the (HindHI to HindHI) portion of the 
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promoter and the coding sequences for LacZ (SDK). The resulting construct, pHrtTAXK, 
was digested with Apai and ligated with the HH portion of the promoter previously 
amplified from the pHHSDKXK construct (using primers: 5'-
TGGTACCGGGCCCCCCCT-3' and 5'-TCATCGCGGGCCCTGGTGGCCCT-3') and 
digested with Apai. Orientation of the TIE2 promoter in the construct was verified to be 
as previously described for endothelial specificity 9). The resulting construct 
pHHrtTAXK was digested with Kpnl and the fragment harboring the TIE2 promoter, 
rtTA coding sequence, SV40 poly A site and TIE2 enhancer (TIE2/rtTA/Enh) was used to 
create FVB transgenic mouse lines (Transgenic Core Facility at Children's Hospital 
Research Foundation). 
Genotyping was performed by Southern blot analysis using either a probe 
encompassing the TRE promoter for the TRE/ASTBDN-1 transgenic lines or a probe 
encompassing the coding sequence for rtTA for TIE2/rtTA!Enh lines. Lines positive for 
HHrtTAXK transgene integration were further tested for rtT A protein expression by 
western blot analysis (18) oflysates oftail specimens and by immunohistochemistry of 
the vasculature using an affinity purified rabbit polyclonal antibody that recognizes the 
VP-16 sequence present in the rtTA protein (Clontech, Palo Alto California). FVB 
transgenic lines were backcrossed into the C57BL/6 background. Bitransgenic 
TIE2/rtTA/Enh-TREIASTBDN-1 mice were derived by mating 4 different TRE/ASTBDN-
1 positive lines to 5 different TIE2/rtTA!Enh positive lines. 
For conditional knockdown ofTbdn-1, induction with doxycycline (Dox) was 
performed by feeding animals with commercially prepared mouse chow containing 
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Dox mg/kg [Bio-Serv, New Jersey]). Dox fed mice were sacrificed after various 
time points and tissues were analyzed grossly, histologically and 
immun.ohistochemically. The care use of animals in this study followed the 
guidelines set forward by the Canadian Council on i\nimal Care and were approved by 
the Institutional Animal Care Committee of Memorial University ofNewfoundland. 
experiments involving animals adhered to the ARVO Statement for the Use of Animals 
in Ophthalmic and Vision Research. 
Mouse anti-Tbdn-1 serum 
To generate a mouse anti-Tbdn-1 serum (MS.C10-20TD), mice were immunized with a 
peptide corresponding to the amino acid sequence 10 to 20 of mouse Tbdn-1 (16) coupled 
to the carrier protein cationizied BSA (cBSA) (Pierce, Rockford IL). The specificity of 
the mouse anti-Thdn-1 antiserum was validated by confirming that the recombinant 
Tbdn-1 protein was immunoprecipitated by MS.C10-20TD antiserum. Briefly, in vitro 
translation of Tbdn-1 was carried out with TNT T7 Quick Coupled 
Transcription/Translation System (Promega, Madison WI), using e5s]-
methionine/cysteine and pcDNA3.1-TBDN-1 construct (16). Analysis of 
immunoprecipitations of in vitro translated 35S-labeled Tbdn-1 with the mouse anti-Tbdn-
1 serum MS.C10-20TD was as previously described 8). 
Histology suppressed mice 
Mouse tissues were fixed in 4% paraformaldehyde, embedded in paraffin or methacrylate 
resin and processed for histology and immunohistochemistry as previously described 
8,20). Sections were stained Vilith hematoxylin and eosin (H&E), toluidine blue or with 
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different antibodies. Antibodies used for immunohistochemistry included chicken anti-
Tbdn-1 Ab1272 antibody (16), mouse anti-Tbdn-1 serum MS.C10-20TD, rabbit anti-VP-
16 (Clontech, Palo California), rabbit anti-Von Willebrand Factor (vWF [DAKO, 
Glostrup Denmark]), rabbit anti-laminin (DAKO, Glostrup Denmark), mouse anti-glial 
fibrillary acidic protein (GF AP) and mouse anti-alpha smooth muscle actin (ASMA 
[Sigma, St. Louis, MO]). Mouse anti-basement membrane heparan sulfate proteoglycan 
(HSPG) antibodies C17 (21) and 33 (22) were obtained from the Developmental Studies 
Hybridoma Bank (University of Iowa). Immunohistochemical reactions were developed 
using species appropriate secondary antibody (Promega, Madison WI) conjugated to 
alkaline phosphatase or horseradish peroxidase. Sections destined for peroxidase 
development were previously incubated in 0.3% hydrogen peroxide for 10 minutes to 
block endogenous peroxidase activity. Prior to incubation with anti-laminin, tissues were 
digested with 0.1% trypsin at 35°C for 20 minutes. Mouse antibodies were applied 
following a 30 minute incubation in rabbit anti-mouse blocking preparation. 
The sections were counter-stained with methyl green and mounted in Permount. 
Blood vessel counts 
Blood vessels in mouse liver, kidney cortex, brain ventricle and testes were identified by 
immunostaining with vWF and/or laminin specific antibodies as described above. 
Pictures of ten random non-overlapping microscopic fields (250x magnification, 
35200j.Lm2) within at least two independent sections for each treatment (two specimens 
per treatment) were captured and the number of blood vessels counted in each field. The 
total number of blood vessels for each tissue per specimen was calculated and compared 
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between transgenic specimens. Blood vessel counts in mouse retina and choroid were 
based on photographed H&E and Trichrome stained sections. Blood vessels from 
approximately ten microscopic pictures spanning each retina and choroid from 
control mice (n=7; Dox-induced TIE2/rtTA/Enh and wild-type mice) and pathological 
retinal lesions regions ofDox-induced TIE2/rtTA/Enh-TREIASTBDN-1 mice (n=5) and 
were counted for each retinal layer and standardized by dividing the blood vessel count 
by both the length and area of the corresponding retinal layer. Damaged pictures were 
removed from the analysis. Pictures were taken using a Qimaging CCD camera and 
analyzed with Openlab software (Improvision, Guelph, ON). 
2.5 RESULTS 
Conditional knockdown of Tbdn-1 in endothelium of TIE2/rlTAIEnh-TRE/ASTBDN-1 
bitnmsgenic mice 
To explore the role ofTbdn-1 in endothelium in vivo, a binary antisense TBDN-1 
(ASTBDN-1) transgenic mouse model (TRE/ASTBDN-1 and TIE2/rtTA/Enh) driven by 
the tetracycline responsive element (TRE) and the rtTA eDNA under the control of the 
TJE2 endothelial promoter was generated to conditionally suppress Tbdn-1 expression 
upon doxycycline (Dox) treatment. The TIE2 promoter confers transgene expression in 
all endothelial cells, including retinal endothelium in vivo 9). Expression rtT A 
protein in the vasculature of mouse lines identified to contain the TIE2/rtT A!Enh 
sequences was confirmed by western blot and immunohistochemical analysis of tissues 
such as the endocardium bone marrow vessels compared to non-transgenic 
control mice (Fig. 2-la, 2-lb and not shown). Mice harboring TIE2/rtTAI Enh and 
2-10 
TRE/ASTBDN-1 transge:nes were treated Dox and analyzed for the efficacy to 
specifically suppress Tbd:n-llevels in endothelium. Dox-i:nduced TIE2/rtTA/Enh-
TREIASTBDN-1 mice showed suppression ofTbd:n-1 protein expression in both retinal 
blood vessels and bone marrow blood vessels compared to double transgenic :non-
induced animals or single transge:ne Dox-induced controls (Fig. 2-lc:fand :not shown). 
To confirm that the knockdown of Thd:n-1 expression in the retinas of double induced 
transgenic mice does :not result from the loss of retinal blood vessels, basal lamina of 
retinal blood vessels of either :non-induced or Dox-i:nduced TIE2/rtTA/Enh-
TREIASTBDN-1 were stained for lamini:n. Lami:ni:n staining of sections adjacent to those 
showing Tbd:n-1 suppression revealed the presence of complex vascular :networks, 
confirming specific Tbd:n-1 suppression rather than the loss of retinal blood vessels in 
Dox-induced TIE2/rtTA/Enh-TREIASTBDN-1 mice (Fig. 2-lg and 2-lh). Moreover, 
lamini:n staining of the basal lamina of retinal blood vessels indicated a focal increase in 
blood vessel density in Thd:n-1 suppressed retinas compared to control specimens (Fig. 2-
lg, 2-lh, 2-5a and 2-5b). 
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Conditional knockdown of Tbdn-1 in endothelium results in preretinal fibrovascular 
lesions retina-lens adhesions 
Morphological assessment of retinas in Dox-induced TIE2/rtTA/Enh-TREIASTBDN-l 
mice exhibiting Tbdn-1 suppression in endothelial cells (n=15) revealed a phenotype 
characterized by the focal or localized formation of preretinal membranes displaying 
retinal neovascularization, fibrovascular growth and retina-lens adhesions (Fig. 2-lc-h, 2-
6). Knockdovvn of Tbdn-1 in retinal blood vessels resulted in abnormal retinal blood 
vessel structures and patterns (Fig. 2-lh, 2-2c-f, 2-4, and 2-5b). The inner layers ofthe 
retina (GCLIIPLIINL; see Fig. 1-1) in Thdn-1 suppressed mice showed a statistically 
significant (p<0.05) 3.0 fold increase in the number of retinal capillaries per length of 
retina compared to control retinas (Fig. 2-3). However, the number of retinal blood 
vessels per area of each retinal layer is not increased in mice exhibiting Tbdn-1 
suppression in comparison with control mice due to retinal thickening corresponding with 
the retinal neovascularization. There was no significant difference in the number of blood 
vessels in the outer retina layers (OPLIONL/PHR; see Fig 1-1) or the choriocapillaries in 
Tbdn-1 suppressed mice compared to control mice (Fig 2-3). Retinal and vitreal tissues of 
Tbdn-1 suppressed mice contained tortuous, highly branched vasculature enlaced in a 
fibrovascular material extending beyond the vitreo-retinal boarder (Fig. 2-lh, 2-2c-f, 2-4, 
and 2-5b ). Some capillaries within the retinal lesions appeared abnormally elongated and 
distended. contrast, both Dox-induced TRE/ASTBDN-1 and Dox-induced 
TIE2/rtTA!Enh control mice (n=25), as well as non-induced TIE2/rtTA!Enh-
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TRf>'ASTBD>.;-1 mice (.....6) did not sbo" Tbdn-1 suppre<"on or an} ocular palholc>g} 
(Fii. 2-lc-c. 2-lg. 2-28. 2-2b. 2-4a. 4c,2- 4e. 2-Sc. and 2-Sd). 
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The retinal pathology Dox-induced TJE2/rtTA!Enh-TREIASTBDN-1 mice 
increased in severity with prolonged suppression of endothelial-derived Tbdn-1 
expression (Fig. 2-4), while control mice did not show retinal pathology with prolonged 
Dox induction. TIE2/rtTAIEnh-TREIASTBDN-1 mice induced with Dox for 2 weeks 
presented with a focal pathology including thickening of the retina and the initial 
formation of a preretinal membrane harboring neovascular elements (Fig. 2-4a and 2-4d). 
Six weeks after suppression of Thdn-1 in endothelium, the retinal fibrovascular lesions 
increased in size (Fig. 2-4b and 2-4e) with some specimens exhibiting retinal-lens 
adhesions and penetration of aberrant blood vessels through the lens capsule into the lens 
(Fig. 2-2e and 2-2./). At a period of 10 to 12 weeks ofThdn-1 suppression, the 
fibrovascular lesions of the retina often filled the vitreal space and adhered to the lens 
(Fig. 2-2d, 2-4c and 2-4./). 
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•-/. Rettnll' from 17f:1.·rtTAIF.n~TR£JAST8Dlv'-1 mice after two wcckt of Do" induc:tion (a and b) show 
C:'ttdCJK:C: O( ftdS(;I!OI blood \'esstl! and fibrovascular prolifcratkln. lhe \e\'trll)' of patholog}· Of retina] 
k:o\iont '"'~~~~ \\ith Oo't-induction or six \\'tds (c and J) and ten wcch (• and/). The arTOWS point to 
~ .. b.:ullll'i~Mion oc:curnn~ w1thin the fibro,·asc:uLilt &ok'lns. I he: bo\c~ 1n a. c. and e indicate arns of 
peth(lloo .,ho""n 11 h1gh<r lnlgfliriCilioo io b. J. IDd f. mpt\.1i\tl)- \.t.aanificataon: o. c, and ,. ( lOOXl; b. 
J. 11/l>Jf (2'10X). H .!t ~ ""inin& (<>d); Toluidm< btu< ""'"'"I(< 11/l>J/J. (1.~ lcou; (V~ ..;""""" ("-R~ 
nourol mona. Scale ._. <qUailS pm. 
Tbd11-l supprns•d millall..suJfl< displ11y llbflor,.,.j lli>trlburio" of ECW, 
ffi)'Ojibroblasts afld 11lial cdls 
To further characterize the fibrovascular lc>ion> a.._ toted with endothelial 
kn<>ckdown of lbdn-1, expression panems of ECM oomponent~ were analyzed by 
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immunohistochemistry in Dox-induced TJE2/rtT A/Enh-TREI ASTBDN-1 mice. Laminin 
expression was utilized as a marker to label the abnormal retinal vascular network in 
Dox-induced TIE2/rtTA/Enh-TREIASTBDN-1 mice as well as normal blood vessels of 
control retinas (Fig. 2-5). Sections adjacent to those stained for laminin were analyzed 
for the expression of basement membrane HSPG using two different anti- basement 
membrane HSPG monoclonal antibodies (C17 and 33). Results using both anti-HSPG 
antibodies revealed that the expression of basement membrane HSPG in blood vessels 
comprising Tbdn-1 suppressed retinal lesions was very low or un-detected compared to 
HSPG expression in normal retinal blood vessels expressing normal levels of Thdn-1 
(results using antibody C17 shown in Fig. 2-5c and 2-5d). Furthermore, knockdown of 
Tbdn-1 expression in endothelium resulted in a global decrease in retinal basement 
membrane HSPG expression, including retinal blood vessels localized outside the 
fibrovascular lesions in areas where the retinal morphology appeared normal (Fig. 2-5e 
and 2-5/J. 
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Figun- 2-5: Endothtlbll knockdown ofll>dn-1 result.~ in supprt5.sion of HSPG e'Cprenion in retinal 
blood Ve$$tiS 
tr and h, Laminin staining (bro", horseradish peroxidase staining) labels the basal lamina of vessels 
(arro...,."'td) rt\ttaling tbe wsc:ular networb present in the recina of both noo-inducod control (o) and 6 "'-eek 
Oox-induc:cd T/£1/nTA/Enh-TRFJASTBDN-1 mice (b). Laminin expression patterns re"•eal an increase in 
recinal blood vessels in Dox·induced n£2/rtT A!Enh-TREIASTBDN-1 mice showing suppressed Tbdn-1 
levels (b). c and d. In contrast to nonnal vessels in non-induced fle.JirtTAJ£nh-1'R£)AS1'BDN-1 mina (c), 
,·essels (arrowed) present in the retinal fibrovaseular tesions ofTbdn-1 suppressed mice (6 week Dox· 
induced TJE21nTA!Enh-Tk£1AS1'8DN-1) show low or no staining (broYm staining) for HSPG (d). e and/ 
Ocular ''essels outside fibrovascular lesions (arrowed) in Dox-induced TIE21rtTA.IEnh-TREJASTBDN-1 
m~ also show nonnal levels of laminin staining (e) but suppressed levels of HSPG (/) compared to control 
mioe expressing normal levels ofTbdn-1 (a and c. rcspccrively). Ma.gr.iftca.tion; a-f(2SOX). Counterstain in 
all panels is methyl green. (V). vitreous: (NR). neural retina: (L). Lens; (LS). retinal lesion. Scale bars 
equai2S Jim. 
To further characterize the cell typeS present in tl1e retinal lesions ofTbdn-1 
suppressed mice, retinas ofDox-induced TIE2/rtTA/Enh-TREIASTBDN-l mice were 
analyzed for the expression of A SMA, a myotibroblast cell marker, and GFAP, a glial 
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cell marker. Expression of ASMA was detected in the fibrovascular lesions ofDox-
induced TIE2/rtTA/Enh-TREIASTBDN-J mice (Fig. 2-6a). ASMA positive staining in the 
retinal lesions appeared to be concentrated around larger blood vessels in a continuous 
pattern, rather than compact staining of small retinal capillaries that would indicate the 
nonnal pericytic coverage of vessels. ASMA staining outside the retinal lesions in Tbdn-
1 suppressed animals displayed an expression pattern similar to pericyte staining in 
control retinas (Fig. 2-6c and data not shown). Fibrovascular retinal lesions resulting 
from Thdn-1 suppression also showed an increase in the number of cells positive for 
GF AP staining compared to control retinas expressing nonnallevels of Tbdn-1 (Fig. 2-6b 
and 2-6d). However, the increase in GF AP positive cell number in Thdn-1 suppressed 
retinas was restricted to the fibrovascular lesions (data not shown). 
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Figure 2-6: FibrO\'as.tular lesions in Tbdn-1 suppres$td re.tinas ~ontain myofibroblasts and glial eell$ 
41 and c, ASMA immunostaining (brown reddish staining, arrowed) of a fibrovasc.ulut retinal lesion from u 
6 ...,--eek Dox-indooed Tl£1/rtTAI£n/t.TREIASTBDN-J mouse (o) re,•eals largo abnormal \'Cssels containing 
myofibcoblast cells (brocket) while immunostaining outside lhe lesion displays a normal pauem (c). band 
d, GFAP i:mmunohi~ochemistl)' (brown horseradish peroxidase staining) of retinas trom 6 wcdc Oox· 
induced Tl£2/rtTA!Enh-Tk.£/AST'BDN-1 mice (b) reveal an increase in the number of glial cells (arrowed) 
in fibrQ,•ascular tissue (bracket) of retinal lesions compared to control retina expressing normal levels of 
Thdn .. J (d). Ma.gnifie<ltion: o..J(IOOX). Counterstain in both panels is methyl green. (V). vitreous; (NR), 
neuml retina; (L), lens. Scale bars cqual25 J.lffl. 
2-21 
Pathology associated endothelial knockdown of Tbdn-1 is limited to the retina 
Since the TIE2 pan endothelial promoter was utilized for targeting expression of 
antisense TBDN-1 exclusively to all endothelial cells, it is conceivable that the 
vasculature of tissues other than the retina might be susceptible to the potentially 
deleterious effects of Tbdn-1 suppression. To address this issue, several adult tissues of 
Dox-induced TIE2/rtTA/Enh-TREIASTBDN-1 mice were analyzed in comparison to 
controls for pathology and for blood vessel integrity using endothelial cell and blood 
vessel markers. All other adult tissues examined (heart, bone marrow, salivary gland, 
lung, spleen, liver, kidney, brain, and testes) showed no discernable gross or histological 
pathology of the tissues or blood vessels (not shown). Kidney, liver, brain, and testes 
from Dox-induced TIE2/rtTA/Enh-TREIASTBDN-1 mice all showed no difference in 
overall blood vessel density compared to controls (Fig. 2-7 and not shown). Therefore, 
the neovascularization as well as the pathological changes evident in Dox-induced 
TIE2/rtTA/Enh-TREIASTBDN-1 mice appear to be specific to the retina. 
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Figure 2-7: Blood vessel density in kidneys of Tbdn-1 suppressed mice is similar to control mice 
Kidney sections from Dox-induced TIE2/rtTA/Enh-TREIASTBDN-J mice at both 6 and 10 weeks ofDox 
induction (BITRANSGENIC 6 wk and BITRANSGENIC 10 wk, respectively) showed no difference in 
overall blood vessel density compared to non-induced wild-type (WT -),non-induced TIE2/rtTA!Enh-
TREIASTBDN-l (BITRANSGENIC -),and 6 week Dox-induced single transgenic (TRE/ASTBDN-1 6 wk 
and TIE2/rtT A/Enh 6 wk) controls as indicated. Bars represent standard deviations. 
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2.6 DISCUSSION 
The suppression of Tbdn-1 expression in mouse endothelium results in several 
pathological features observed in human proliferative retinopathies including retinal 
neovascularization, preretinal fibrovascular proliferation and retinal-lens adhesions. 
Manipulation of specific protein expression has previously been demonstrated to induce 
retinal neovascularization in vivo. Previously described models of neovascular 
retinopathy include the overexpression of specific growth factors. Transgenic mouse 
models conferring VEGF overexpression in the retina have proven sufficient to cause 
retinal neovascularization which progresses to tractional retinal detachment (23-24). 
Transgenic mice overexpressing PDGF-B in photoreceptors soon after birth develop 
retinal lesions harboring glial, endothelial and pericyte elements also leading to retinal 
detachment (25). In contrast to the ocular specific phenotype resulting from Thdn-1 
suppression, the effects of endothelial ablation ofPDGF-B and over-expression ofVEGF 
are not restricted to the ocular vascular bed with consequences observed in other vascular 
networks (26-29). In the adult, high levels ofTbdn-1 expression are restricted to 
specialized vasculature including ocular blood vessels, bone marrow capillaries, atrial 
endocardium and blood vessels of regressing ovarian follicles (16-17). The restriction of 
pathological changes to the retina in Dox-induced TIE2/rtTA!Enh-TREiASTBDN-l mice 
indicates that the effects resulting from Thdn-1 suppression in endothelium is highly 
specific to retinal blood vessels. The lack of pathology in other adult tissues might be 
explained either by the absence of Tbdn-1 expression in the corresponding vascular bed 
6-1 or by the absence of a critical binding partner or cofactor important for mediating 
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Tbdn-1 activity in the given tissue. Such possible binding partners might include 
mammalian orthologues of the yeast ARD 1 acetyltransferase (30-31 ). Possible 
mechanisms of action of the Tbdn-1 pathway may include affecting the stability and/ or 
activity of proteins involved in regulating angiogenesis through acetylation. Recent 
studies indicate that the mammalian acetyl transferase ARD 1 plays a role in the targeted 
degradation ofHIF-la (32). HIF-1a regulates VEGF expression during hypoxia (33). 
Therefore, acetyl transferase complexes involving ARD 1 or Tbdn-1 represent new 
candidates for upstream regulators of cytokines and growth factors which could control 
retinal neovascularization. Upstream regulators of signaling cascades controlling 
angiogenesis in the retina could offer new molecular based therapeutic targets for treating 
neovascular retinopathies. 
In the present study, we find that the proliferative retinopathy resulting from 
suppression of Thdn-1 expression in endothelium in mice is accompanied by a global 
decrease of basement membrane HSPG expression in retinal blood vessels. Although the 
thickening and alteration of the vascular basement membrane are well known features 
associated with proliferative retinopathies, the mechanisms that regulate these processes 
are not completely elucidated (12, 34). Basement membrane ECM constituents provide a 
tissue specific barrier between endothelial cells and underlying connective tissues and 
participate in controlling angiogenesis (35). Altered expression patterns ofECM 
constituents could promote the disorganization and breakdown of vascular basement 
membranes and eventually lead to endothelial cell proliferation (35). The loss ofHSPG 
from basement membranes has been implicated in the breakdovvn of blood vessel 
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integrity in diabetic nephropathy (36-38). Moreover, retinas of diabetic rats show a 
decrease in the synthesis and expression of the HSPG perlecan (39). HSPG can regulate 
the activity of angiogenic factors (e.g. VEGF, bFGF) by regulating the binding to their 
respective receptor on endothelial cells ( 40-41 ). Our results indicate that Tbdn-1 is an 
upstream regulator of HSPG expression in blood vessel basement membranes in the 
retina. Currently, it is not dear if suppression of basement membrane HSPG in retinal 
blood vessels of Tbdn-1 suppressed mice is the result of a reduction in HSPG synthesis or 
an increase in HSPG degradation. Future studies will focus on the identification of 
specific basement membrane HSGPs regulated by Tbdn-1 and the mechanisms of action 
underlying this process. 
Although retinal detachment is common in later stage PDR, in rodents retinal 
detachment is rare (42). Nevertheless, the retinal pathology in Dox-induced 
TIE2/rtTA/Enh-TREIASTBDN-1 mice displays several features which could promote 
tractional retinal detachment. The Tbdn-1 suppressed retinas display retinal-lens 
adhesions and invasion of the lens capsule and lens by blood vessels from the adjacent 
fibrovascular lesional tissue. Also, the fibrovascular lesions in Tbdn-1 suppressed retinas 
show an increase in the number of cells expressing the glial marker GF AP compared to 
control retinas. In conjunction with an increase in GF AP-positive cells, the 
myofibroblastic marker ASMA is increased in large caliber blood vessels the Tbdn-1 
suppressed retinal lesions. Myofibroblasts expressing ASMA and glial cells expressing 
GF AP are thought to exert contractile forces which promote tractional retinal detachment 
in neovascular retinopathy ( 43-49). The presence of ASMA expressing myofibroblasts 
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and GF AP expressing glial cells in Tbdn-1 suppressed lesions supports the view that the 
exertion of contractile forces and subsequent tractional retinal detachment is possible in 
advanced retinal lesions of Thdn-1 suppressed mice. However, this cannot be 
confirmed histologically due to potential artifacts inferred by tissue processing. 
The conditional knockdown of Tbdn-1 in endothelium in the TIE2/rtT A/Enh-
TRE/ASTBDN-1 bitransgenic model clearly provides evidence for the necessity ofThdn-1 
expression for the maintenance of adult retinal blood vessel homeostasis by suppressing 
abnormal retinal blood vessel growth. The phenotype associated with Tbdn-1 suppression 
in endothelium resembles the sight disrupting pathology observed in human proliferative 
retinopathy. This, together with our previous evidence of Tbdn-1 suppression in the 
retinal endothelium in patients with PDR (17), supports the hypothesis of a contributing 
role for loss of Thdn-1 expression in the progression of proliferative retinopathies. Thdn-
1 may serve as a valuable pathway for developing new therapies aimed at controlling 
proliferative retinopathies. 
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3 SUMMARY 
Blinding neovascular ocular diseases are characterized by a disparity in the 
equilibrium between prmmgiogenic and antiangiogenic molecular determinants. A 
molecular shift favoring a pro-angiogenic microenvironment stimulates 
neovascularization, fibrovascular scar formation and retinal detachment, all hallmarks of 
several common sight threatening diseases such as PDR, the "wet" form of macular 
degeneration and ROP. A comprehensive understanding of the molecular mechanisms 
driving the pathophysiology resulting in these phenotypic responses is necessary in 
preventing and treating neovascular ocular disease. 
Previous in vitro and in vivo evidence suggest that Tbdn-1 functions as a 
homeostatic modulator during the maturation and quiescence of retinal vascular networks 
(Gendron eta!. 2000; Gendron et al. 2001; Paradis et al. 2002). Tbdn-1 is suppressed in 
neovascular areas of retinal endothelium in patients with diabetic retinopathy, the leading 
cause of blindness in the working age population in developed nations (Gendron et al. 
2001 ). For the purpose of investigating the role of Tbdn-1 in retinal endothelium in vivo, 
a mouse model was developed utilizing the Dox controlled tet-on system and taking 
advantage of the tie2 pan endothelial promoter for targeting expression of an ASTBDN-1 
eDNA exclusively to endothelial cells (Sato et al. 1993). Confirmation of the efficacy of 
this system to down-regulate Tbdn-1 levels endothelium was accomplished using 
immunohistochemical analysis of rtT A and Tbdn-1 protein expression. 
The present study has reinforced our hypothesis that Tbdn-1 regulates retinal blood 
vessel homeostasis by demonstrating in vivo the retinal consequences of specifically 
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suppressing Thdn-1 protein expression in endothelium. Knockdown of Thdn-1 protein 
expression endothelial cells results in the formation of pre-retinal membranes, retinal 
neovascularization, and cellular proliferation of contractile cells such as glial and 
myofibroblastic cell types. This phenotype potentially promotes vision loss in several 
ways. The formation of neovascular lesions extending from the inner retina and filling 
the vitreous chamber may structurally obscure the passage of light photons through the 
lesioned retina to the sensory photoreceptor cells. The pathological blood vessels 
constituting the lesions are likely leaky, as the capillaries are distorted and specifically 
down-regulate basement membrane constituent HSPG, resulting in leakage of fluid from 
the capillaries into the retina and vitreous promoting vitreal hemorrhage. Also, the 
presence of the contractile cell types may promote the traction of the retina thereby 
tearing the retina from the RPE. However, the definitive diagnosis of retinal detachment 
in mice is difficult due to potential artifacts during tissue processing (Smith 2002). This 
work implicates Tbdn-1 as an important regulatory protein in retinal vascular biology in 
vivo. Tbdn-1 expression in adult retinal endothelium is a necessary negative modulator 
ofblood vessel remodeling. Loss ofthe Tbdn-1 protein in retinal capillaries may 
promote endothelial cell outgrowth to form vascular networks. 
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